BioSpace News Archive

Infinity Pharmaceuticals, Inc. today announced that Adelene Perkins, Chief Executive Officer, will give a corporate presentation at 7:30am ET on January 13, 2022 at the 40th annual J.P. Morgan Healthcare Conference, taking place virtually.

Virtue Diagnostics, an innovative IVD company, has just announced closing US$100 million in Series B funding. Virtue Diagnostics, founded in 2019, is focused on clinical tests for China and emerging markets.

Marrone Bio Innovations, Inc., an international leader in sustainable bioprotection and plant health solutions, announced it has relocated its corporate headquarters from Davis, California, to Raleigh, North Carolina, to support the company’s growing presence in markets outside the United States.

Neovasc, Inc. announced that its management team will be participating in the 2022 H.C. Wainwright BIOCONNECT Virtual Conference to be held January 10-13, 2022.

Amgen and Generate Biomedicines announced a research collaboration agreement to discover and create protein therapeutics for five clinical targets across several therapeutic areas and multiple modalities.

Alphatec Holdings, Inc., a provider of innovative spine surgery solutions dedicated to revolutionizing the approach to spine surgery, announced that Pat Miles, Chairman and Chief Executive Officer, and Todd Koning, Chief Financial Officer, will present at the 24th Annual Virtual Needham Growth Conference on January 14, 2022, at 1:15pm ET.

Deep Genomics to Present at the 40th Annual J.P. Morgan Healthcare Conference.

PharmaCyte Biotech, Inc., a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced that it will be featured as a presenting company at the H.C. Wainwright BioConnect Conference.

Strata Oncology, Inc., a precision oncology company advancing molecular indications for cancer therapies, today announced that its co-founder and Chief Executive Officer, Dan Rhodes, Ph.D., will present at the 40th Annual J.P. Morgan Health Care Conference, being held virtually from January 10-13.

DEINOVE (Euronext Growth Paris, ALDEI), a French biotech company, pioneer in the exploration and exploitation of bacterial biodiversity to address the urgent, global challenge of antibiotic resistance, announced today that the independent Data Safety Monitoring Board (DSMB) has completed its review of the safety data from the first part of the Phase II clinical trial of DNV3837 in the treatment of Clostridioides difficile infection (CDI).